51³Ô¹ÏºÚÁÏ

It’s called the Chambers-Grundy Center for Transformative Neuroscience at 51³Ô¹ÏºÚÁÏ, and the adjective in the name says it all.

The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed new data that highlights wasted expenditures from Alzheimer trials and the importance of understanding their impacts.

Pharmacological studies have attempted and failed for past decades to generate medicines that might halt the course of the illness. Now, experts claim to have reached a tipping point in Alzheimer's development.

The cause of Alzheimer’s was supposedly simple.

Alzheimer’s treatments seemed unlikely just a few months ago.

A week ago, Brigham and Women's Hospital announced it would spearhead the first human trial of a nasal spray vaccine as a protection against Alzheimer's disease, formulated to prevent or delay the progression of the disease.

Last week, Brigham and Women's Hospital announced that it would pioneer a trial using a spray drug for Alzheimer's disease.

Alzheimer's treatments were not considered likely just months ago.